Optimal approach to T-cell ALL.
Hematology Am Soc Hematol Educ Program
; 2022(1): 197-205, 2022 12 09.
Article
em En
| MEDLINE
| ID: mdl-36485091
ABSTRACT
T-lineage acute lymphoblastic leukemia (T-ALL) is curable for most children and adolescent and young adult patients with contemporary frontline chemotherapy regimens. During the past decade, improved survival rates have resulted from the optimization of frontline chemotherapy regimens, the use of minimal residual disease (MRD) assessment for evaluating a patient's risk for relapse, and the intensification of treatment based on the persistence of MRD. Optimization of initial therapy is critical because relapsed T-ALL after initial intensive chemotherapy is incurable for most adult patients. Current T-ALL salvage chemotherapy regimens are minimally effective, and unlike in B-cell ALL, there are no approved antibody therapies or chimeric antigen receptor T-cell therapies for relapsed disease. Immunotherapy and small-molecule inhibitors are beginning to be tested in relapsed T-ALL and have the potential to advance the treatment. Until effective salvage strategies are discovered, however, intensive frontline therapy is required for cure. In this article I review the current frontline chemotherapy regimens for adult patients with T-ALL, summarize the novel targeted and immune therapeutics currently in early-phase clinical trials, and outline how these therapies are helping to define an optimal approach for T-ALL.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
Limite:
Adolescent
/
Adult
/
Child
/
Humans
Idioma:
En
Revista:
Hematology Am Soc Hematol Educ Program
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2022
Tipo de documento:
Article